Spirovant
Pausa
About Spirovant
Spirovant is focused on changing the course of cystic fibrosis and other pulmonary diseases. Their gene therapy technologies are designed to overcome the historical barriers that have prevented effective genetic treatments for cystic fibrosis.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 11 – 50
- Estimated revenue: $1K – $10K
- Total funding: $4.7M
- Last round: Grant (Jan 2019)
- Website: spirovant.com
- Phone: +267 244 8206
Industries & Categories
Biotechnology, Genetics, Medical
Social Profiles
Canonical: https://fsome.com/organization/spirovant-9230 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.